Assessment and management of left ventricular hypertrophy in Type 2 diabetes patients with high blood pressure. (June 2013)

• Record Type: Journal Article
• Authors: Derosa, Giuseppe; Maffioli, Pamela
• Is Part Of: Expert review of cardiovascular therapy. Volume 11:Number 6(2013)
• Page Start: 719
• Page End: 728
• Publication Date: 2013-06
• Subjects: hypertension -- left ventricular hypertrophy -- therapy -- Type 2 diabetes mellitus; Cardiovascular agents -- Research -- Periodicals; 616.12061
• DOI: 10.1586/erc.13.36
• Languages: English
• ISSNs: 1477-9072

Abstract

Diabetes is associated with left ventricular hypertrophy (LVH). This article reviews the assessment and management of LVH in Type 2 diabetic patients and the available evidence on blood-pressure management in these patients in order to reduce LVH. The best treatment of LVH starts with early identification and rapid implementation of adequate treatment, especially in populations at higher risk. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors should be the first-line therapy, because they are proven to be the most effective in reducing LVH in Type 2 diabetic patients. In patients where angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors are contraindicated or not tolerated, calcium-channel blockers should be the second option.